GlassScriptPhysician profile
Sheikh Tejan-Sie
NPI 1346237617
$11,798.56
in general payments reported to CMS, 2019-2025
55 companies · $1,219 in 2025
The $1,219 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,636 · 2020: $1,367 · 2021: $2,109 · 2022: $2,658 · 2023: $1,537 · 2024: $1,273 · 2025: $1,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,029.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,863.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,038.41 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Preventric Diagnostics, INC. | $676.22 | 2022 | |
| Amgen INC. | $667.08 | 2019-2024 | Repatha, Otezla |
| Esperion Therapeutics, INC. | $620.15 | 2020-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $573.84 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $551.13 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Lilly USA, LLC | $505.08 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $491.36 | 2019-2025 | Jardiance |
| Abbvie INC. | $458.36 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| E.R. Squibb & Sons, L.L.C. | $419.80 | 2020-2023 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $351.26 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $293.56 | 2019-2024 | Xarelto, Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $289.03 | 2023-2025 | |
| Eisai INC. | $255.67 | 2020-2022 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheikh Tejan-Sie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.